Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

NCT00901927 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Study was closed early due to toxicity

Conditions

Follicular Lymphoma

Interventions

DRUG: Bendamustine
DRUG: Mitoxantrone
DRUG: Rituximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]